STOCK TITAN

MDB Capital Holdings (MDBH) Stock News, Jul-Nov 2024

MDBH NASDAQ

MDB Capital Holdings, LLC reports developments as a public venture platform and investment holding company focused on launching and supporting disruptive technology companies. Its news commonly covers shareholder updates, operating results, portfolio-company positions, capital-market services and the activity of subsidiaries that combine broker-dealer, intellectual property and technology-development functions.

Company updates also feature PatentVest, MDB’s intellectual property intelligence, strategy and legal-services business. Recurring PatentVest releases discuss IP landscape reports, patent strategy, legal insights, biotechnology and medical-technology collaborations, and equity-linked service engagements that connect patent research, due diligence and venture formation.

Rhea-AI Summary

Invizyne Technologies (NASDAQ: IZTC) has been awarded a $2 million project from the U.S. Department of Defense's BioMADE initiative to advance sustainable aviation fuel (SAF) capabilities. The project, in partnership with the University of Georgia, focuses on enabling enzyme production for cell-free biomanufacturing of isobutanol, a key SAF precursor. This follows previous grants totaling $5.85 million from the Department of Energy. The project aims to develop an enzyme production pipeline and deploy technology in 100L pilot-scale facilities. The global SAF market is projected to grow at 52.2% annually, reaching $27.4 billion by 2032.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.10%
Tags
none
-
Rhea-AI Summary

MDB Capital Holdings (NASDAQ: MDBH) has scheduled a Zoom webinar for Thursday, November 21, 2024, at 4:30 p.m. Eastern Time to discuss its third quarter 2024 results. CEO Christopher Marlett will lead the presentation, accompanied by management team members, to review recent developments, ongoing initiatives, and anticipated milestones. The company will release detailed financial results before the call. Investors can pre-register for the webinar through a provided link or access it via MDB's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
conferences earnings date
-
Rhea-AI Summary

Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced the closing of its Initial Public Offering of 1,875,000 common stock shares at $8.00 per share. Trading began on NASDAQ under symbol IZTC on November 13, 2024. The IPO raised approximately $15 million in gross proceeds. The company granted a 45-day option to the underwriter to purchase up to 281,250 additional shares. Additionally, in a concurrent private placement, Invizyne issued 93,750 warrants at $0.125 each, exercisable at $8.00 per share for five years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
Rhea-AI Summary

Invizyne Technologies (NASDAQ:IZTC), a designer of cell-free, enzyme-based biomanufacturing systems, began trading on Nasdaq on Nov. 13, 2024. The company, founded in 2019, is based on technology developed by UCLA Professor Emeritus James Bowie that enables enzymatic pathways to function outside living cells. CEO Michael Heltzen emphasized the company's ability to overcome traditional cell-based synthetic biology limitations through their next-generation enzymes and biomanufacturing platform, aiming to demonstrate commercial viability through licensing deals and partnerships.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
IPO
-
Rhea-AI Summary

Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced that its common shares will begin trading on the NASDAQ on November 13, 2024, at approximately 12:00pm EST under the ticker symbol 'IZTC'. The company specializes in producing commercially important molecules and chemicals for everyday life through their innovative biotechnology solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
none
-
Rhea-AI Summary

Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced that its common shares will begin trading on the Nasdaq Capital Market on November 13, 2024, under the ticker symbol 'IZTC'. The company, which focuses on producing commercially important molecules and chemicals for everyday life, expects the offering to close on November 14, 2024, subject to customary closing conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
none
Rhea-AI Summary

Invizyne Technologies has announced the pricing of its Initial Public Offering of 1,875,000 common stock shares at $8.00 per share, raising $15 million in gross proceeds. Trading will begin on Nasdaq under ticker 'IZTC' on November 12, 2024. The company granted a 45-day over-allotment option for 281,250 additional shares and will issue 184,375 warrants in a concurrent private placement. Proceeds will fund production expansion, business development, sales and marketing, loan repayment, and working capital. The offering is expected to close on November 13, 2024, with MDB Capital acting as underwriter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
-
Rhea-AI Summary

MDB Capital Holdings, (NASDAQ: MDBH) has announced its sponsorship of TCA Venture Group, one of the largest angel investor networks in Southern California. The partnership, which began in August 2024, aims to provide TCA's angel investors with insights into public venture investing and potential future collaboration opportunities.

As part of this initiative, MDB will share deep tech insights and co-host events with TCA. The first joint event is scheduled for October 21, 2024, featuring Lou Basenese, MDB Capital President & Chief Market Strategist, and Dave Berkus, TCA Chairman Emeritus, discussing 'Traditional Venture vs Public Venture'. This virtual event is open to all individual and angel investors.

The sponsorship is expected to support TCA through events across its network and assist portfolio companies with their exit plans. Both organizations express excitement about the collaboration and its potential benefits for entrepreneurs and investors in the innovation industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
-
Rhea-AI Summary

MDB Capital Holdings has announced the record date and expected timing for the IPO of its subsidiary, Invizyne Technologies. The record date for allocation preferences is set for July 22, 2024, with the IPO expected to close and start trading on NASDAQ on or before August 15, 2024. Invizyne, specializing in cell-free, enzyme-based biomanufacturing systems, aims to raise $17.2 million by offering 4,300,000 shares at $4.00 per share. MDB Class A shareholders will have allocation preferences in this IPO, with additional shares potentially available on a pro-rata basis. Interested investors must contact MDB Capital by August 5, 2024, to indicate the number of shares sought.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
Rhea-AI Summary

PatentVest, a leading IP intelligence strategy and law firm, recently published a whitepaper exploring innovations in MASH (Metabolic-Associated Steatohepatitis) diagnostics. The document offers strategic insights into MASH biomarkers and Point of Care (PoC) kits for detecting and monitoring this condition. Key drivers include the recent approval of the MASH drug, Rezdiffra, and an increase in patenting activities. Emerging patent opportunities are identified in non-invasive diagnostic techniques, multi-biomarker tools, and personalized medicine approaches. This whitepaper aims to guide stakeholders in navigating the competitive landscape by leveraging innovation and IP protection. The full report is available on the PatentVest website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
none

FAQ

What is the current stock price of MDB Capital Holdings (MDBH)?

MDB Capital Holdings (MDBH) last closed at $1.46.

What is the market cap of MDB Capital Holdings (MDBH)?

The market cap of MDB Capital Holdings (MDBH) is approximately $15.2M.